MM

Mariana Mihalusova

Investor | Drug Developer

San Francisco Bay Area

Invests in

  • Min Investment:

    $3,000,000.00
  • Max Investment:

    $10,000,000.00
  • Target Investment:

    $6,500,000.00

Education

Work Experience

  • Board Observer

    2024

  • Board Observer

    2023

  • Board Member

    2022

  • Board Observer

    2021

  • Board Observer

    2020

2020

  • Vice President

    2020

2012 - 2020

  • Executive Director, Global Project Leadership, Research & Early Development

    2017 - 2020

    Celgene was acquired by Bristol-Myers Squibb Company in Nov 2019. Led drug development efforts for 15 compounds (small molecules, biologics, engineered cell therapies) in hematology, oncology, inflammation/immunology, and neurodegenerative diseases. Responsible for the formulation and execution of global integrated development strategies, including scientific rationale, clinical development, budget, regulatory, and technical strategies. Managed large, cross-functional teams comprised of discovery, clinical, clinical operations, translational, regulatory, IP, commercial, CMC, toxicology, DMPK, clinical pharmacology, drug safety, medical affairs, and market access.

  • Senior Director, Global Project Leadership, Research & Early Development

    2015 - 2017

  • Director, Global Project Leadership, Research & Early Development

    2015 - 2015

  • Associate Director, Global Project Leadership

    2014 - 2015

  • Sr. Manager, Global Project Leadership

    2012 - 2014

2004 - 2010

  • Graduate Research Assistant / Teaching Fellow

    2004 - 2010

    Research areas: single-molecule/nanoscale imaging and analysis, telomerase structure and function Teaching Fellow: Molecular Pathophysiology and Pharmacology of Human Disease, Molecular Genetics of Neural Development and Behavior, and Molecular Biology.